Key Highlights
- Oxford Nanopore Technologies Plc (LSE:ONT) shares rose 9.51% on 30 September 2026, touching a new 52-week high of about 218.4p.
- A major Investment bank raised its price target to 210p from 195p with a buy rating on 22 September, a level the stock has now surpassed.
- The Unified Patent Court granted a preliminary injunction against MGI Tech GmbH on 16 September, strengthening Oxford Nanopore's intellectual property position.
- Insiders have bought nearly 16,000 shares in recent months, and the stock has more than doubled from its July low of 95.7p.
Momentum Accelerates
Oxford Nanopore Technologies Plc (LSE:ONT) was one of the strongest FTSE 250 performers on 30 September 2026, gaining 9.51%. The shares had closed at 199.4p on 29 September after hitting a 52-week high, and today's gain pushed them to around 218p. The stock has risen in most sessions over the past two weeks, climbing more than 18% over that period even before today's move.
Why Oxford Nanopore Is in Focus
LSE:ONT is one of the UK's most prominent life sciences technology companies. It develops nanopore-based sensing technology that can read DNA and RNA in real time, with applications across research, clinical diagnostics, biopharma, and applied markets such as food safety and infectious disease surveillance. Its portable and scalable sequencing devices differentiate it from larger rivals.
The company has been through a period of Leadership change. Francis Van Parys became chief executive in March 2026, succeeding co-founder Gordon Sanghera. Interim results published on 19 August were the first under the new leadership and triggered a strong rally, as investors welcomed a narrower loss and improving margins.
Key Reasons Behind Today's 9.51% Rise
The first driver is analyst momentum. On 22 September a major investment bank raised its target price to 210p from 195p and kept a buy rating. With the shares now well above that level, investors appear to be pricing in further upgrades. Market consensus shows five buy ratings and one hold.
The second is the patent win. The Unified Patent Court granted a preliminary injunction against MGI Tech GmbH on 16 September, reinforcing Oxford Nanopore's competitive moat in sequencing technology and potentially limiting competitive pressure in European markets.
The third Factor is insider buying. Company insiders, including a purchase of 15,325 shares on 4 September, have added to their holdings, signalling confidence in the company's direction.
The fourth factor is technical strength. The stock is trading well above its 50-day and 200-day moving averages, which attracts momentum-driven funds.
Financial Trajectory
For 2025, Oxford Nanopore reported Revenue of £223.9 million, up 22.2%, while adjusted losses narrowed to £86.7 million from £117.9 million. The company expects constant-currency revenue growth of 21% to 25% in both 2026 and 2027 and continues to target adjusted EBITDA breakeven in the 2027 financial year, followed by Cash Flow breakeven in 2028. Trailing revenue now stands at about £235 million.
The path to profitability is central to the investment case. Each step toward breakeven reduces the risk that the company will need to raise more capital.
What Investors Are Watching
Investors will track sequencing volumes and consumables growth, adoption in clinical and biopharma markets, gross Margin progress, and any further legal developments in patent disputes. Updates on cost control and the timetable to EBITDA breakeven will be particularly important.
Risks
Oxford Nanopore remains loss-making and competes with well-funded global sequencing companies. Research funding cycles, particularly in academic markets, can affect demand. The stock's rapid rise also increases the risk of profit-taking.
Outlook
Today's 9.51% gain to a new 52-week high reflects a convergence of analyst support, legal success and insider confidence. If the company continues to deliver on growth and cost targets, LSE:ONT could extend its recovery further.






Please wait processing your request...